Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: BUY (auto-tracking)
1.60% $6.97
America/New_York / 23 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 301.15 mill |
EPS: | -0.510 |
P/E: | -13.67 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 43.21 mill |
Avg Daily Volume: | 0.395 mill |
RATING 2024-04-23 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -13.67 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.06x |
Company: PE -13.67 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 6.58 - 7.36 ( +/- 5.57%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-16 | Zaderej Karen L. | Buy | 84 847 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 975 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 166 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 500 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 086 | Common Stock |
INSIDER POWER |
---|
41.85 |
Last 98 transactions |
Buy: 1 200 055 | Sell: 468 598 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.97 (1.60% ) |
Volume | 0.165 mill |
Avg. Vol. | 0.395 mill |
% of Avg. Vol | 41.64 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $9.87 | N/A | Active |
---|
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.